To include your compound in the COVID-19 Resource Center, submit it here.

AstraZeneca sales and marketing update

AstraZeneca launched Bydureon Pen for self-injection of once-weekly Bydureon exenatide in the U.S. to treat Type II

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE